| 3.89 -0.26 (-6.27%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.38 |
1-year : | 6.02 |
| Resists | First : | 4.6 |
Second : | 5.15 |
| Pivot price | 4.6 |
|||
| Supports | First : | 3.72 |
Second : | 3.09 |
| MAs | MA(5) : | 4.4 |
MA(20) : | 4.55 |
| MA(100) : | 3.75  |
MA(250) : | 3.23 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 33 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 7.36 | Low : | 1.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ARTV ] has closed below the lower bollinger band by 13.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ARTV ] is to continue within current trading range. Bollinger Bands are 36.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.22 - 4.26 | 4.26 - 4.28 |
| Low: | 3.66 - 3.69 | 3.69 - 3.71 |
| Close: | 3.84 - 3.9 | 3.9 - 3.94 |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Sun, 01 Feb 2026
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest - MarketBeat
Wed, 21 Jan 2026
Artiva Biotherapeutics Announces Upcoming Presentations at - GlobeNewswire
Thu, 15 Jan 2026
Artiva Biotherapeutics Stock: Upcoming Data Presentations In Focus (NASDAQ:ARTV) - Seeking Alpha
Wed, 17 Dec 2025
ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView
Mon, 15 Dec 2025
Artiva Biotherapeutics CEO sells $19,122 in stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 24 (%) |
| Held by Institutions | 74.1 (%) |
| Shares Short | 391 (K) |
| Shares Short P.Month | 160 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -48 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -77 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -3.14 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|